RT Journal Article SR Electronic T1 Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: a study protocol for an Expanded Access Programme JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.11.28.22282846 DO 10.1101/2022.11.28.22282846 A1 Bourner, Josephine A1 Redji Mbrenga, Festus Devincy A1 Malaka, Christian Noël A1 Dunning, Jake A1 Rojek, Amanda A1 Fandema, Emmanuel A1 Horby, Peter A1 Boum, Yap A1 Nakouné, Emmanuel A1 Olliaro, Piero YR 2022 UL http://medrxiv.org/content/early/2022/11/29/2022.11.28.22282846.abstract AB Background Monkeypox is a viral zoonotic disease commonly reported in humans in parts of Central and West Africa. This protocol is for an Expanded Access Programme (EAP) to be implemented in the Central African Republic, where Clade I monkeypox virus diseases is primarily responsible for most monkeypox infections. The objective of the programme is to provide patients with confirmed monkeypox with access to tecovirimat, a novel antiviral targeting orthopoxviruses, and collect data on clinical and virological outcomes of patients to inform future research.Methods The study will be conducted at participating hospitals in the Central African Republic. All patients who provide informed consent to enrol in the programme will receive tecovirimat. Patients will remain in hospital for the duration of treatment. Data on clinical signs and symptoms will be collected every day while the patient is hospitalised. Blood, throat and lesion samples will be collected at baseline and then on days 4, 8, 14 and 28. Patient outcomes will be assessed on Day 14 – end of treatment – and at Day 28. Adverse event and serious adverse event data will be collected from the point of consent until Day 28.Discussion This EAP is the first protocolised treatment programme in Clade I MPXV. The data generated under this protocol aims to describe the use of tecovirimat for Clade I disease in a monkeypox endemic region of Central Africa. It is hoped that this data can inform the definition of outcome measures used in future research and contribute to the academic literature around the use of tecovirimat for the treatment of monkeypox. The EAP also aims to bolster research capacity in the region in order for robust randomised controlled trials to take place for monkeypox and other diseases.Trial registration {2a & 2b}ISRCTN43307947View this table:Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN43307947Funding StatementThe funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This Expanded Access Programme was approved by the University of Oxford Tropical Research Ethics Committee (ref: 1-20) and the University of Bangui Scientific Research Ethics Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not Applicable I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.CARCentral African RepublicCo-ICo-InvestigatorCRFCase Report FormDProgramme dayIBInvestigator’s BrochureIMPInvestigational Medicinal ProductNTDNeglected Tropical DiseasePIPrincipal InvestigatorPISPatient Information SheetRCTRandomised Controlled Trial